Schonfeld Strategic Advisors LLC Protagonist Therapeutics, Inc Transaction History
Schonfeld Strategic Advisors LLC
- $13.8 Billion
- Q3 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 61,026 shares of PTGX stock, worth $2.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
61,026
Previous 49,064
24.38%
Holding current value
$2.3 Million
Previous $1.7 Million
61.29%
% of portfolio
0.02%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$220 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$217 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$204 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$120 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.85B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...